CHS 131

Drug Profile

CHS 131

Alternative Names: AMG 131; INT 131; INT131 besylate; T 0903131; T 131

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Tularik
  • Developer Coherus Biosciences; InteKrin Therapeutics
  • Class Anti-inflammatories; Insulin sensitisers; Neuroprotectants; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 2 diabetes mellitus

Most Recent Events

  • 14 Sep 2016 Adverse events data from a phase II trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 28 Jun 2016 Efficacy data from a phase IIb trial in Multiple sclerosis released by Coherus BioSciences
  • 07 Aug 2015 INT 131 is still in phase II development for Type-2 diabetes mellitus in USA and Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top